MedImmune, Roche and Genechem previously backed Ambit Biosciences, which is nearly to closing latest round.
Ambit Biosciences, an anti-cancer drugs developer formerly known as Aventa Biosciences, has raised $15m of a planned $15.9m round of debt, rights and securities from 18 investors, according to a recent regulatory filing first seen by news provider Xconomy.
Ambit raised $49.3m in its series D round in 2007, led by venture capital firm Apposite Capital and including corporate venturing from MedImmune Ventures, which is now part of AstraZeneca; Roche Venture Fund; and Genechem. The other VCs…
